Top 10 New Entrants companies in PCSK9 Inhibitors by Most Patent Filing In 3 Years in the world in 2022 – Discovery

Free Trial

The PCSK9 Inhibitors top 10 is Discovery PatSnap’ annual ranking of the top 10 Most Patent Filing In 3 Years PCSK9 Inhibitors New Entrants in the world. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2022, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.

Ranking Year:

Region:

Ranking:

1	AstraZeneca UK Ltd.	Cambridgeshire, United Kingdom	Gastrointestinal infections,Medicine,Simvastatin, ...[+2]	Patent: 20
2	AstraZeneca Plc	Cambridgeshire, United Kingdom	Medicine,Health care,Side effect, ...[+2]	Patent: 20
3	STARTUP Dogma Therapeutics, Inc.	Massachusetts, United States	PCSK9,Cardiovascular agent,Biophysics, ...[+2]	Patent: 3
4	Manchester University NHS Foundation Trust	Manchester, United Kingdom	Health care,Hospitality industry	Patent: 2
5	The Kitasato Institute	Tokyo, Japan	Medical research	Patent: 2
6	Daegu-Gyeongbuk Medical Innovation Foundation	South Korea	Biopharmaceutical	Patent: 2
7	Kyungpook National University Industry-Academic Cooperation	Daegu, South Korea	Asset management,Impact investing,Social Welfare	Patent: 2
8	Université de Lorraine	LORRAINE, France	Merger process,Cell encapsulation,Tissue engineering, ...[+2]	Patent: 1
9	Kyungpook National University Hospital		Medicine,Internal medicine,Surgery, ...[+2]	Patent: 1
10	Tsinghua University Shenzhen Graduate School	CN		Patent: 1